Resource Centre
)
Introductory guide: unlocking the biopharma development pipeline with Oxford Nanopore
- AAV
- Biopharma
- Direct analysis
- Amplicons
- Plasmid
- mRNA
April 16 2025
)
Recombinant AAV batch profiling by nanopore sequencing elucidates product-related DNA impurities and vector genome length distribution
- AAV
- Biopharma
- MinION
- Plasmid
January 21 2025
rAAV genome sequencing uncovers transgene integrity and packaging impurities
- AAV
- Infectious disease
- Biopharma
May 13 2024
)
Quality control for adeno-associated virus genome preparations using nanopore sequencing
- AAV
- Microbiology
- Biopharma
- Clinical research
May 8 2024
)
Navigating cell and gene therapy: the benefits of whole-genome profiling
- AAV
- Biopharma
- Plasmid
- Webinar
March 25 2025
Evaluation of the loading capacity and patterns of packaged DNA in AAV genomes of different sizes using long-read sequencing
- AAV
- Biopharma
- MinION
April 19 2025
Enhancing cell and gene therapy success with multi-omic sequencing
- AAV
- Biopharma
- Webinar
- Plasmid
November 15 2024
Contaminating manufacturing plasmids and disrupted vector genomes present in liver tissue following adeno-associated virus gene therapy
- AAV
- Biopharma
- Human genomics
- PromethION
- MinKNOW
January 14 2025
)
Brochure: EPI2ME — data analysis for all levels of expertise
- AAV
- 16S
- AMR
- Assembly
- Bacteria
- Bioinformatics
May 1 2025
A single amino acid variant in the variable region I of AAV capsid confers liver de-targeting
- AAV
- Biopharma
- Plasmid
- Amplicons
March 5 2025